Published in Eur J Immunol on February 02, 2011
Vaccine-induced myeloid cell population dampens protective immunity to SIV. J Clin Invest (2014) 1.64
Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother (2012) 1.55
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. Cancer Cell (2016) 1.44
The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth. BMC Cancer (2016) 1.39
The spleen in local and systemic regulation of immunity. Immunity (2013) 1.33
Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell Mol Life Sci (2013) 1.26
Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets (2011) 1.22
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol (2016) 1.20
Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer (2012) 1.12
Characterization of a novel population of low-density granulocytes associated with disease severity in HIV-1 infection. PLoS One (2012) 1.05
Arginase activity - a marker of disease status in patients with visceral leishmaniasis in ethiopia. PLoS Negl Trop Dis (2013) 1.04
Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron (2012) 1.03
A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res (2013) 1.02
Myeloid-derived suppressor cells contribute to Staphylococcus aureus orthopedic biofilm infection. J Immunol (2014) 1.01
Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity (2014) 1.01
Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. Am J Pathol (2011) 1.01
Increased MDSC accumulation and Th2 biased response to influenza A virus infection in the absence of TLR7 in mice. PLoS One (2011) 1.01
Defective TGF-β signaling in bone marrow-derived cells prevents hedgehog-induced skin tumors. Cancer Res (2013) 1.00
MDSC: a new player in HIV immunopathogenesis. AIDS (2012) 0.93
Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis. J Immunol (2014) 0.90
Wogonin prevents lipopolysaccharide-induced acute lung injury and inflammation in mice via peroxisome proliferator-activated receptor gamma-mediated attenuation of the nuclear factor-kappaB pathway. Immunology (2014) 0.89
Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells. Oncoimmunology (2014) 0.86
Effects of acute and chronic low density lipoprotein exposure on neutrophil function. Pulm Pharmacol Ther (2012) 0.84
Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity. J Immunol (2015) 0.84
Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator. Cancer Immunol Immunother (2015) 0.83
Myeloid-derived suppressor cells: paradoxical roles in infection and immunity. J Innate Immun (2014) 0.83
Toward a molecular pathogenic pathway for Yersinia pestis YopM. Front Cell Infect Microbiol (2012) 0.83
CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro Oncol (2015) 0.80
Inhibition of Hedgehog signaling in the gastrointestinal tract: targeting the cancer microenvironment. Cancer Treat Rev (2013) 0.78
IL-11 induces differentiation of myeloid-derived suppressor cells through activation of STAT3 signalling pathway. Sci Rep (2015) 0.76
The protective role of myeloid-derived suppressor cells in concanavalin A-induced hepatic injury. Protein Cell (2014) 0.76
Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration. ISRN Oncol (2013) 0.76
Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors. Proc Natl Acad Sci U S A (2017) 0.75
Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma. Hum Vaccin Immunother (2015) 0.75
Authors' reply to 'Granulocytic myeloid-derived suppressor cells in peripheral blood of patients with cutaneous melanoma'. Int Immunol (2015) 0.75
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Nitric oxide and the immune response. Nat Immunol (2001) 10.00
Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 9.41
Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol (2005) 9.27
Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 9.25
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood (2008) 7.15
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Arginine metabolism: nitric oxide and beyond. Biochem J (1998) 6.44
Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol (2004) 5.73
MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med (2007) 5.48
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood (2000) 4.78
Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol (2006) 4.43
Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res (2007) 4.39
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00
Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol (2008) 3.91
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88
Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol (1999) 3.68
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res (2010) 3.53
CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol (2007) 3.39
STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol (2005) 3.32
Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol (2009) 3.23
Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol (2005) 3.20
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol (2010) 3.18
iNOS-mediated nitric oxide production and its regulation. Life Sci (2004) 3.10
Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol (2000) 3.07
Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol (2000) 3.01
Enhancer-mediated control of macrophage-specific arginase I expression. J Immunol (2004) 2.95
Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol (2003) 2.94
Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol (2009) 2.90
L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol (2003) 2.81
Inhibition of tumor growth by elimination of granulocytes. J Exp Med (1995) 2.65
Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest (2008) 2.46
Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20
Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol (2009) 2.14
Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol (2009) 1.96
Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol (2008) 1.95
Neutrophil involvement in cross-priming CD8+ T cell responses to bacterial antigens. J Immunol (2004) 1.83
Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol (2008) 1.69
The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res (2009) 1.64
Protein tyrosine nitration--functional alteration or just a biomarker? Free Radic Biol Med (2008) 1.61
Effects of the new arginase inhibitor N(omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide (1999) 1.38
Superantigen-induced CD4 T cell tolerance mediated by myeloid cells and IFN-gamma. J Immunol (2000) 1.28
The importance of myeloid-derived suppressor cells in the regulation of autoimmune effector cells by a chronic contact eczema. J Immunol (2007) 1.21
Successful elimination of memory-type CD8+ T cell subsets by the administration of anti-Gr-1 monoclonal antibody in vivo. Cell Immunol (2003) 1.20
Experimental rodent models of prostatitis: limitations and potential. Prostate Cancer Prostatic Dis (2007) 1.08
N-nitro-L-arginine and N-monomethyl-L-arginine exhibit a different pattern of inactivation toward the three nitric oxide synthases. Arch Biochem Biophys (1995) 1.01
T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction. Prostate (2006) 1.00
IFN-gamma and IL-4 differently regulate inducible NO synthase gene expression through IRF-1 modulation. Int Immunol (2000) 0.99
C/EBP-beta mediates iNOS induction by hypoxia in rat pulmonary microvascular smooth muscle cells. Circ Res (2002) 0.86
Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity (2003) 1.84
Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood (2008) 1.83
Diurnal cortisol variations and symptoms in patients with interstitial cystitis. J Urol (2002) 1.73
An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate. Prostate (2011) 1.68
Cholesterol sulfate imaging in human prostate cancer tissue by desorption electrospray ionization mass spectrometry. Anal Chem (2010) 1.48
Platelet-derived CD154 enables T-cell priming and protection against Listeria monocytogenes challenge. Blood (2008) 1.40
Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol (2007) 1.24
The emerging role of platelets in adaptive immunity. Cell Immunol (2006) 1.19
Prostate inflammation and its potential impact on prostate cancer: a current review. J Cell Biochem (2008) 1.14
Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. J Biol Chem (2011) 1.12
The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology (2011) 1.08
Fat dogs and coughing horses: K-12 programming for veterinary workforce development. J Vet Med Educ (2013) 1.08
Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC. Head Neck (2009) 1.05
Role of FcRgamma and factor XIIIA in coated platelet formation. Blood (2005) 1.02
Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer. Mol Cancer Ther (2012) 1.02
Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res (2009) 1.01
Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. Am J Pathol (2011) 1.01
T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction. Prostate (2006) 1.00
Deletion is neither sufficient nor necessary for the induction of peripheral tolerance in mature CD8+ T cells. Immunology (2006) 0.97
Nuclear factor of activated T cells (NFAT) mediates CD154 expression in megakaryocytes. Blood (2008) 0.96
Synergistic effects of cisplatin chemotherapy and gold nanorod-mediated hyperthermia on ovarian cancer cells and tumors. Nanomedicine (Lond) (2014) 0.96
Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients. Am J Cancer Res (2011) 0.95
Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J Immunol (2003) 0.94
Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation. J Leukoc Biol (2005) 0.92
Platelet CD40L at the interface of adaptive immunity. Thromb Res (2010) 0.90
Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. Int J Cancer (2003) 0.90
The role of platelet CD154 in the modulation in adaptive immunity. Immunol Res (2007) 0.90
α(V)β(6) integrin expression is induced in the POET and Pten(pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma. Am J Transl Res (2012) 0.87
The fibronectin attachment protein of bacillus Calmette-Guerin (BCG) mediates antitumor activity. Cancer Immunol Immunother (2007) 0.86
Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. J Immunol (2012) 0.85
Platelet influence on T- and B-cell responses. Arch Immunol Ther Exp (Warsz) (2009) 0.85
Systemic and cell-specific immune response to laparoscopic and open nephrectomy in porcine model. J Endourol (2008) 0.84
Early microrecanalization of vas deferens following biodegradable graft implantation in bilaterally vasectomized rats. Asian J Androl (2009) 0.83
Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy. Int J Cancer (2006) 0.82
Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Hum Vaccin Immunother (2012) 0.82
Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer. Hum Gene Ther (2006) 0.80
Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). J Urol (2005) 0.78
Immunotherapy of urologic tumors: principles and progress. Urol Oncol (2002) 0.78
Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets. Exp Hematol (2004) 0.78
Urine markers for bladder cancer surveillance: a systematic review. J Urol (2005) 0.78
Ibuprofen inhibits survival of bladder cancer cells by induced expression of the p75NTR tumor suppressor protein. J Urol (2005) 0.77
Structure/function analysis of the murine CD95L promoter reveals the identification of a novel transcriptional repressor and functional CD28 response element. J Biol Chem (2003) 0.77
Fibronectin attachment protein from bacillus Calmette-Guerin as targeting agent for bladder tumor cells. Int J Cancer (2011) 0.76
Early growth response-1 (EGR-1) and nuclear factor of activated T cells (NFAT) cooperate to mediate CD40L expression in megakaryocytes and platelets. J Biol Chem (2013) 0.76
Prostate specific antigen detection in patient sera by fluorescence-free BioCD protein array. Biosens Bioelectron (2010) 0.76
Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. J Urol (2005) 0.76
Mutation of the androgen receptor causes oncogenic transformation of the prostate. J Urol (2005) 0.76
Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium. J Urol (2005) 0.76
Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. J Urol (2005) 0.75
High molecular mass proteome of androgen-independent prostate cancer. J Urol (2005) 0.75
Promotion of carcinogenesis and oxidative stress by dietary cholesterol in rat prostate. J Urol (2005) 0.75
CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. J Urol (2005) 0.75
Genomic Structure of Human OKL38 Gene and its Differential Expression in Kidney Carcinogenesis. J Urol (2005) 0.75
Agents in development for prostate cancer prevention. J Urol (2005) 0.75
bc10: a novel human bladder cancer-associated protein with a conserved genomic structure downregulated in invasive cancer. J Urol (2002) 0.75
Estrogen receptor alpha and imprinting of the neonatal mouse ventral prostate by estrogen. J Urol (2005) 0.75
Central modulation of the NO/cGMP pathway affects the MPOA-induced intracavernous pressure response. J Urol (2002) 0.75
CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas. J Urol (2005) 0.75
Immune gene therapy in urology. Curr Urol Rep (2002) 0.75
Involvement of growth factors in the process of post-vasectomy micro-recanalization. J Urol (2007) 0.75
Robust prostate-specific expression for the targeted gene therapy based on the human kallikrein 2 promoter. J Urol (2002) 0.75
Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro. J Urol (2005) 0.75
The effect of mupirocin- and fusidic acid-nasal packings, placed after septoplasty, on the nasal bacterial profile. Allergy Rhinol (Providence) (2016) 0.75
Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. J Urol (2005) 0.75
Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a toll-like receptor-4-dependent mechanism. J Urol (2005) 0.75
Mast cell regulation of inflammation and gene expression during antigen-induced bladder inflammation in mice. J Urol (2002) 0.75
Contribution of mast cells to bacterial clearance and their proliferation during experimental cystitis induced by type 1 fimbriated E. coli. J Urol (2005) 0.75